In a randomized, open-label, phase II clinical trial (NCT02196181), intermittent dosing of BRAFV600 inhibitor dabrafenib and MEK inhibitor trametinib did not improve progression-free survival in melanoma patients with similar toxicity as in continuous dosing [16]. The gene discussed is MAP2K7; the disease is melanoma.